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Abstract
Objectives—Environmental exposure to multiple metals is common. A number of metals cause
nephrotoxicity with acute and/or chronic exposure. However, few epidemiologic studies have
examined the impact of metal co-exposure on kidney function. Therefore, we evaluated
associations of antimony and thallium with kidney outcomes and assessed the impact of cadmium
exposure on those associations in lead workers.
Methods—Multiple linear regression was used to examine associations between ln-urine
thallium, antimony and cadmium levels with serum creatinine- and cystatin-C-based glomerular
filtration measures, and ln-urine N-acetyl-β-D-glucosaminidase (NAG).
Results—In 684 participants, median urine thallium and antimony were 0.39 and 0.36 μg/g
creatinine, respectively. After adjustment for lead dose, urine creatinine, and kidney risk factors,
higher ln-urine thallium was associated with higher serum creatinine- and cystatin-C-based
estimates of glomerular filtration rate (eGFR); associations remained significant after adjustment
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for antimony and cadmium (regression coefficient for serum creatinine-based eGFR = 5.2 mL/
min/1.73 m2; 95% confidence interval = 2.4, 8.0). Antimony associations with kidney outcomes
were attenuated by thallium and cadmium adjustment; thallium and antimony associations with
NAG were attenuated by cadmium.
Conclusions—Urine thallium levels were significantly associated with both serum creatinine-
and cystatin-C-based glomerular filtration measures in a direction opposite that expected with
nephrotoxicity. Given similarities to associations recently observed with cadmium, these results
suggest that interpretation of urine metal values, at exposure levels currently present in the
environment, may be more complex than previously appreciated. These results also support
multiple metal analysis approaches to decrease the potential for inaccurate risk conclusions.
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antimony; cadmium; creatinine; kidney function; thallium
INTRODUCTION
A number of metals are known or suspected occupational and/or environmental
nephrotoxicants. Lead and cadmium are widely recognized in this regard [1–3]. Recent
advances in analytical technology, allowing measurement of multiple metals in urine
samples, have revealed that most US residents are exposed via the environment to a wide
range of metals [4]. However, data on nephrotoxic effects of metals other than lead and
cadmium are limited and the effect of kidney exposure to multiple metals is relatively
unknown. Populations with co-exposures might be at increased risk for adverse kidney
effects. Antimony and thallium are metals that are nephrotoxic in acute and subacute
exposures [5,6] and are also common environmental exposures as evidenced by
biomonitoring in the US general population [4] wherein urine antimony and thallium were
detectable in 86.7% and 99.9%, respectively, of National Health and Nutrition Examination
Survey (NHANES) 05-06 participants [7]. However, to the best of our knowledge, no
epidemiologic studies have examined associations of urine levels of either metal with kidney
outcomes that include glomerular filtration measures. Therefore, to address the kidney
impact of multiple metal exposures, we performed a cross-sectional analysis examining
associations between urine antimony and thallium levels and kidney outcomes in 684
current and former lead workers in the Republic of Korea in whom cadmium associations
with kidney function have been reported [8,9].
MATERIALS AND METHODS
Study overview and design
We performed a cross-sectional analysis of data from current and former inorganic lead
workers who completed the fourth evaluation in a prospective study. Evaluations were
performed between April 8, 2004 and September 24, 2005. All participants provided written,
informed consent. Participation in the study was voluntary. The study protocol was
approved by Institutional Review Boards at the SoonChunHyang University School of
Medicine and the Johns Hopkins University Bloomberg School of Public Health.
Study population
As previously described [8–10,11], participants in the initial cohort of this study were
recruited between 1997 and 1999 (phase I) for three annual evaluations via medical
surveillance programs at secondary lead smelters and plants that produced lead batteries,
lead oxide, lead crystal, or radiators. The population is 100% Korean. In 2004, recruitment
for three additional annual evaluations (phase II) began; 498 (62%) of the 803 lead workers
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in the original cohort were re-enrolled (many had been laid-off in the economic crisis of the
late 1990s and lost to follow-up) and 279 new participants were recruited. Inclusion criteria
included occupational lead exposure and, for new participants, age ≥ 40 years, in order to
enrich the study with participants with increased risk for adverse kidney outcomes. There
were no medical exclusionary criteria. At the end of the second enrollment phase
(September 24, 2005), 778 current and former lead workers had completed the fourth (initial
phase II) evaluation. In order to optimize study data for both cross-sectional and longitudinal
analyses within funding constraints, a urine metals panel, including thallium, antimony and
cadmium, was measured in fourth evaluation samples in the 712 workers who came to both
the fourth and fifth evaluations. Workers from a primary smelter (n=28) who were enrolled
in the second recruitment phase were excluded from this analysis due to their potentially
wider range of occupational metal exposures, leaving 684 workers for the current cross-
sectional analysis.
Data collection
As previously described [8], data collection and biologic specimens included a standardized,
interviewer-administered questionnaire; blood pressure measured with the IntelliSense™
blood pressure monitor (Model HEM-907; Omron; Vernon Hills, IL); height and weight
measurements; a blood specimen (for serum creatinine, cystatin C and blood lead); four-
hour urine collection (for thallium, antimony, cadmium and creatinine levels); a spot urine
sample (for NAG and creatinine), collected just before beginning the four-hour urine
collection; and tibia lead assessed via X-Ray Fluorescence.
Metals Exposure Assessment
Urine specimens were analyzed for metals in the Trace Elements section of the Laboratory
of Inorganic and Nuclear Chemistry at the New York State (NYS) Department of Health’s
Wadsworth Center (Albany, NY, USA) which is the principal reference laboratory for the
measurement of trace metals in urine in NYS. A multi-element method based on inductively
coupled plasma mass spectrometry (ICP-MS) was used [12]. As previously described [8–
12], the method has been validated against the National Institute of Standards and
Technology (NIST) Standard Reference Materials 2670a Toxic Elements in Urine, as well
as secondary reference materials from a number of External Quality Assessment Schemes in
which the lab participates successfully.
Urine specimens for trace metals analysis were collected and stored at −80°C in 5-mL
Nalgene Cryogenic polypropylene tubes. Urine concentrations of thallium (m/z=205),
antimony (m/z=121), and cadmium (m/z=114) were measured in standard mode using an
Elan DRC II inductively coupled plasma mass spectrometer (PerkinElmer Life and
Analytical Sciences, Shelton, CT) equipped with dynamic reaction cell (DRC-ICP-MS)
technology. As previously described [8–12], 500 μL of urine was diluted 1+19 with 2% (v/
v) HNO3 (Veritas double-distilled; GFS Chemicals, Powell, OH), 0.005% Triton X-100 as a
surfactant (Sigma-Aldrich, St. Louis, MO), 1 mg/L gold and 10 μg/L gallium, rhodium,
yttrium, and iridium (Spex Certiprep, Inc., Metuchen, NJ) as internal standards. Multi-
element calibration standards were prepared by serial dilution of NIST-traceable stock
solution (High Purity Standards, Charleston, SC) using a six point calibration curve for each
element. Base human urine pools were used to matrix-match the calibration standards.
Samples were prepared under conditions (Clean Room and Class IIB Biosafety Cabinet)
certified as Class 100 or better to minimize the potential for contamination.
Quality control (QC) during the course of the study included analysis of urine-based internal
quality control (IQC) materials before, during and after every analytical run. The mean
coefficients of variation (CV) of the IQC samples from 18 days over the five-month period
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in which the samples were assayed were, for antimony, 10% at 0.81 μg/L (n=74), 9.1% at
2.8 μg/L (n=74), 5.5% at 4.5 μg/L (n=62), and, for thallium, 8.5% at 0.25 μg/L (n=74),
8.9% at 0.70 μg/L (n=74), 5.3% at 0.95 μg/L (n=62). One thallium value was below the
method detection limit (MDL) of 0.02 μg/L; median (range) CV was 3.2 % (0.1–17.9) from
60 (8.8%) duplicate analyses (e.g., inter-assay CV). Of the antimony results, 313 (45.8%)
were below the MDL of 0.2 μg/L; median (range) CV was 5.5 % (0.1–73.4 [of 9 CVs that
were > 20%, 8 were from samples that were below the MDL]) from 60 duplicate analyses.
Details of cadmium QC and correction for potential polyatomic interference from
molybdenum were as previously published [8]. None of the results for cadmium were below
the MDL of 0.02 μg/L; median (range) CV was 2.6% (0.2–19.1) based on 60 duplicate
analyses.
Blood lead was measured with a Hitachi 8100 Zeeman-background-corrected atomic
absorption spectrophotometer [13] (Hitachi Ltd. Instruments, Tokyo, Japan) at the Institute
of Industrial Medicine (now the Institute of Environmental & Occupational Medicine), a
certified reference laboratory for lead in South Korea. Tibia lead levels were assessed via a
30-minute measurement of the left mid-tibia diaphysis using 109Cd in a back-scatter
geometry to fluoresce the K-shell X-rays of lead. The lead X-rays were recorded with a
radiation detector and then quantified and compared to calibration data to estimate the
concentration of lead in bone [14–16].
Kidney Outcome Assessment
Serum and urine creatinine were measured via a Dimension® clinical chemistry system
using a Flex reagent cartridge in a modified kinetic Jaffe assay (model RxL; Dade Behring,
Glasgow, DE, USA). Serum cystatin C was measured using an automated Dade Behring
nephelometry assay on a Dimension Vista Lab System (Siemens Healthcare Diagnostics,
Deerfield, IL, USA). Urine NAG concentration was determined using a colorimetric assay
(PPR Diagnostics Ltd, London, UK). For QC purposes, the original serum creatinine and
cystatin C results were ordered by concentration and five percent of each was selected
sequentially for duplication. Median inter-day CV for serum creatinine and cystatin C and
urinary NAG samples run in duplicate were all < 10%.
Calculated creatinine-based kidney outcomes included calculated creatinine clearance
[17]; measured creatinine clearance ([urinary creatinine in mg/dL × urine volume in
mL] / serum creatinine in mg/dL / collection time in minutes); and the Modification of
Diet in Renal Disease (MDRD) creatinine-based eGFR:
• 186.3 × (serum creatinine)−1.154 × (age)−0.203 × 0.742 (if female) [18,19].
Three cystatin-C-based equations were also used to estimate GFR [20]:
• single variable CYSeGFRs = 76.7 × serum cystatin C−1.19
• multivariable CYSeGFRm = 127.7 × serum cystatin C−1.17 × age−0.13 × 0.91 if
female
• Combined cystatin C/creatinine eGFRc = 177.6 × serum creatinine−0.65 ×
serum cystatin C−0.57 × age−0.20 × 0.82 if female
Statistical Analysis
The goals of this analysis were to: 1) evaluate the respective associations between urine
antimony and thallium levels and kidney outcomes inlead workers, while controlling for
covariates; and; 2) to evaluate the effects of adjustment with the other urine metals on those
associations (e.g., urine cadmium and antimony on models with thallium), also controlling
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for covariates. Statistical analysis was performed using statistical software of the StataCorp
LP (College Station, TX) [21].
Initially, variable distributions were examined. Both urine antimony and thallium, with and
without adjustment for urine creatinine (μg/g creatinine) were right skewed and thus ln-
transformed to minimize influential outliers. The NAG distribution also exhibited a non-
normal distribution and was ln-transformed; the efficacy of this transformation was
confirmed by examination of the final regression model residuals. In linear regression
models, urine metals were adjusted for urine dilution in two ways: via the traditional
approach in which the metal concentration is divided by urine creatinine; and via a more
recent approach in which the urine metal and urine creatinine are both included as separate
covariates in the model [22]. Antimony was initially analyzed using all data reported from
the laboratory; subsequently it was determined that 45.8% of values were below the MDL.
Analyses including antimony were then rerun with values below the MDL replaced by
MDL/square root of 2 [23]. Results of this sensitivity analysis were consistent; hence results
using actual values are reported. A sensitivity analysis using only antimony values above the
method detection limit was also performed and discussed below.
Covariate selection utilized a priori variables (age, sex, BMI [weight in kilograms divided
by the square of height in meters], and ln-urine creatinine) in modeling that initially included
urine antimony or thallium with other biologically relevant variables in separate models.
Variables were retained in the final model if they substantially changed either the urine
antimony or thallium regression coefficient or the explanatory value (r2) of the model for
any of the kidney outcomes, or were statistically significant, or were relevant based on a
priori knowledge or hypotheses inherent to this study (e.g. blood and tibia lead; ln-urine
cadmium). Additional covariates considered for inclusion using this approach were diabetes
and hypertension (both based on participant report of physician diagnosis or medication
use); regular analgesic use (based on questionnaire data on medication usage); self-reported
work status (current vs. former lead worker); study status (phase I vs. II study participant),
systolic and diastolic blood pressure (average of three measures); tobacco use (smoking
status: never, former, current); smoking dose [(cigarettes per day × years of smoking) in
quartiles for current smokers and dichotomized for former smokers; alcohol consumption
(never, former, current)]; education (< middle school graduate, < high school graduate, high
school graduate, > high school graduate) and annual income (≤ 10, 10–20, 20–30, 30–40,
and > 40 million won). Blood lead, tibia lead and urine cadmium were added to final models
after all other covariates were selected. Job duration (years) was also added to the final
antimony models because urine antimony is considered a recent occupational exposure
measure in study participants employed in lead battery manufacturing facilities, and job
duration may therefore approximate duration of antimony exposure.
Associations between each study metal were also examined in models stratified at the
median of the respective outcome measure in order to assess the potential for reverse
causality (i.e., whether associations were present only in participants with worse kidney
function). Models were evaluated for linear regression assumptions and the presence of
outlying points using augmented component-plus-residual plots and added-variable plots
[24,25]. Models were repeated without outliers when applicable. Models were also assessed
for collinearity via examination of variance inflation factors.
RESULTS
Selected Demographics, Exposure, and Health Outcome Measures
Information on demographics, metal dose biomarkers, kidney outcomes, and selected
covariates is presented in Table 1 for all 684 lead workers and, separately, by current and
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former lead worker employment status. Males and current lead workers comprised 78.2 %
(n=535) and 65.8% (n=450), respectively, of the population. Median urine thallium and
antimony levels were 0.39 and 0.36 μg/g creatinine, respectively. Median antimony levels
were substantially higher in current than former workers (0.77 and 0.1 μg/g creatinine,
respectively), consistent with current occupational exposure. Mean values of the glomerular
filtration measures were within normal limits.
Exposure biomarkers were generally correlated (Table 2). Higher urine cadmium levels in
former workers, but higher blood lead and urine antimony levels in current workers, were
responsible for the lack of correlation between these metals. For example, antimony was
positively correlated with cadmium in separated current and former worker groups (r=0.15,
0.16, respectively, p<0.05 for both), but not when all workers were considered together
(−0.06, p=0.49). Urine thallium and cadmium were correlated with blood and tibia lead in
current, but not former workers.
Kidney outcomes and urine creatinine were also correlated (Appendix Table 1). Correlations
were generally higher for measures based on the same biomarker (e.g., serum creatinine-
based measures). Urine creatinine was not correlated with any cystatin C variables.
Associations of Urine Metals with Kidney Outcomes
In all lead workers, after adjustment for age, sex, BMI, current vs. former lead worker status,
phase I vs. II study entry, annual income, education, alcohol consumption, smoking dose,
diastolic blood pressure, blood lead, tibia lead, and, in antimony models only, lead job
duration, higher urine concentrations of antimony and thallium (in separate models) were
significantly associated with higher NAG, a direction consistent with nephrotoxicity (Table
3, Models 1 and 2, respectively).
Ln-urine thallium was associated with 7 of the 8 serum creatinine and cystatin-C-based
glomerular filtration measures but the direction of each of these associations was opposite to
that expected with traditional nephrotoxicity (Tables 3 and 4, Model 2). Ln-urine antimony
was only associated with serum creatinine-based glomerular filtration measures (serum
creatinine and MDRD eGFR; a borderline significant association (p < 0.1) with calculated
creatinine clearance was also observed) (Tables 3 and 4, Model 1). As with ln-urine
thallium, the directions were opposite that expected in nephrotoxicity. Neither thallium nor
antimony was associated with measured creatinine clearance.
The direction of significant associations in fully adjusted models was the same in a priori
models that adjusted only for age, sex, BMI and ln-urine creatinine (data not shown).
Adjustment for blood and tibia lead attenuated the associations between ln-urine thallium
and kidney outcomes (although they remained highly significant) but slightly increased the
beta coefficients of the associations between ln-urine antimony and the creatinine-based
glomerular filtration measures.
Associations After Adjustment for Multiple Metals
Associations with each urine metal were evaluated following additional adjustment for the
other metals, e.g., antimony further adjusted for thallium (Tables 3 and 4, Model 3) and for
thallium and cadmium (Tables 3 and 4, Model 4). Previously significant associations with
creatinine-based filtration outcomes were attenuated, however thallium associations
remained significant. With the exception of the combined creatinine- and cystatin-C-based
eGFR, beta coefficients for ln-urine thallium associations with cystatin-C-based filtration
measures became stronger with additional adjustment. Results were consistent when the
metal concentrations were entered as μg/g creatinine (Appendix Table 2). The impact of
cadmium adjustment on each metal is shown in Appendix Table 3.
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Adjustment for metals that were strongly associated with kidney outcomes also had a large
impact on urine creatinine associations. An example is the increased significance of urine
creatinine in Models 2–4 for MDRD eGFR and CYSeGFRm compared to Model 1 (Tables 3
and 4). Associations between urine metals and kidney outcomes, fully adjusted as in Model
4, but without urine creatinine, are shown in Appendix Table 4. With the exception of
measured creatinine clearance, thallium associations were attenuated but remained
significant for cystatin-C-based outcomes. Cadmium associations with serum creatinine-
based outcomes were attenuated but were strengthened for cystatin-C-based outcomes.
Sensitivity Analyses
In order to determine if the observed thallium and cadmium attenuation of antimony
associations was related to measurement uncertainty (45.8% of antimony values were <
MDL), sensitivity analyses, in which values below the MDL were replaced by MDL/square
root of 2, were conducted in models of MDRD eGFR. Similar evidence of attenuation of
associations in combined metal models was observed (data not shown). Models were also
run only in those participants with antimony values > MDL; attenuation, although observed,
was less than when concentrations < MDL were included (data not shown).
To determine if the unexpected directions of the thallium and antimony associations were a
result of different groups within our population, a priori models of MDRD eGFR stratified
by worker status (current versus former) were examined. The directions of the associations
in these analyses were consistent with results in the combined population (data not shown).
Similarly, consistent directions were observed in a priori models of MDRD eGFR stratified
by participant sex (data not shown). In models stratified by median kidney outcome (Table
5), higher ln-urine thallium was associated only in the group of lead workers with worse
kidney function (although in this occupational population, most kidney function values in
this group were still in the normal range making any assessment for reverse causality
difficult).
Similar results were observed in a priori models (data not shown).
In order to determine whether the thallium associations could be due to lead-related
hyperfiltration, fully adjusted models were examined in 234 former lead workers whose
blood lead levels were negatively associated with MDRD eGFR (β [95% CI] = −0.5 [−0.8,
−0.1]), a pattern consistent with traditional lead-related nephrotoxicity. However, urine
thallium remained positively associated with MDRD eGFR in these workers as well (β [95%
CI] = 7.0 [1.9, 12.1]).
DISCUSSION
We compared associations of ln-urine antimony and thallium concentrations with a range of
kidney outcomes, including eight serum creatinine and cystatin-C-based glomerular
filtration measures and NAG, a proximal tubular early biological effect marker, to determine
the impact of co-exposure to these metals on kidney function in lead-exposed workers. Two
key findings were observed. First, contrary to expectation, higher ln-urine thallium levels
were significantly associated with higher levels of both serum creatinine- and cystatin-C-
based glomerular filtration measures (Tables 3 and 4). These associations, which are in the
opposite direction of those traditionally reported in nephrotoxicity, remained significant
even after adjustment for ln-urine cadmium and antimony, and lead dose. Measured
creatinine clearance was an exception; no significant associations with ln-urine antimony or
thallium were observed. In subgroup analyses stratified by median kidney outcome, ln-urine
thallium associations were limited to participants in the lower kidney function group (Table
5). Second, the analysis of multiple metals revealed evidence of attenuation. Antimony
Shelley et al. Page 7
Occup Environ Med. Author manuscript; available in PMC 2013 October 01.
$watermark-text
$watermark-text
$watermark-text
associations with kidney outcomes, only present with creatinine-based outcomes but in the
same unexpected direction, became non-significant after thallium and cadmium adjustment
(Table 3). Similarly, associations of NAG with both antimony and thallium were attenuated
by cadmium adjustment (Table 3).
Thallium and antimony are widespread in the environment. Exposure sources in the general
population include industrial releases, from smelting of other metals and coal combustion,
and diet due to uptake of metals from soil [4,26,27]. Elevated levels of thallium have been
reported in trout from Lake Michigan [28]. In contrast to cadmium, urine levels of antimony
and thallium reflect more current exogenous exposure [4]. Thallium is concentrated in the
kidneys; the half-life in rats is approximately three days; data in humans are extremely
limited but the half-life appears to be as long as 30 days [26]. A renal excretion half-life of
four days for antimony was reported in lead battery production workers although a longer
half-life may be possible based on reports of elevated urine levels in treated patients and
deposits in lungs of smelter workers [27]. In our population, median urine thallium levels
were similar between current and former lead workers (0.40 and 0.37 μg/g creatinine,
respectively) but urine antimony levels were higher in current workers (0.77 cf. 0.10 μg/g
creatinine in former workers), likely from occupational exposure to antimony used as an
alloy in lead storage batteries. In comparison, median and 95th percentile urine levels in
adults in the 2003–2004 NHANES were 0.15 and 0.33 μg/g creatinine, respectively, for
thallium, and 0.08 and 0.28 μg/g creatinine, respectively, for antimony [4].
Nephrotoxicity is a side effect of pentavalent antimony use in the treatment of parasitic
diseases, such as leishmaniasis [29]. Increased serum creatinine, blood urea nitrogen and
proteinuria have been observed in animal models following 30 days of intramuscular
injections with pentavalent antimony compounds [30]. Tubular necrosis and decreased
creatinine clearance have also been reported [29]. Interestingly, consistent with our results
before adjustment for the other metals, decreased serum creatinine was observed in a dose-
related manner in rats exposed to trivalent antimony salt via drinking water over a 90-day
study period [31]. Route of administration may be relevant in animal data; nephrotoxicity
from antimony potassium tartrate administered intraperitoneally but not via drinking water
has been reported [32]. Tubular changes have also been observed in rabbits after five days of
inhalational exposure to antimony trisulfide [33]. A recent analysis of NHANES data
identified antimony as a potential risk factor for peripheral arterial disease [34] and for
cardiovascular and cerebrovascular disease [35].
Acute kidney injury has been reported in thallium poisoning [36–38]. Increased serum
creatinine and proteinuria and decreased GFR have been observed with acute exposure in
animal studies [39–41]. Pathologic changes have been reported throughout the renal tubule
following acute and subacute thallium exposure in animal studies [36–39,42–44]. Decreased
reabsorption in the proximal tubules, even without visible microscopic pathology, has also
been observed [40]. We did not identify any comparable publications on associations
between antimony or thallium and the kidney outcomes used in this analysis. Thallium was
not associated with vascular outcomes in the NHANES analyses cited above for antimony
[34,35].
The data herein allow additional consideration of the previously published hypotheses [8,9]
generated for associations between ln-urine cadmium and serum creatinine-based filtration
measures that were also in the opposite direction to that expected in nephrotoxicity. In the
current analyses, we modeled traditional serum creatinine-based kidney outcomes and
measured creatinine clearance in a four-hour urine collection. We also included the kidney
proximal tubule biomarker, NAG, as well as kidney outcomes based on serum cystatin C, a
cysteine protease inhibitor that is secreted by all nucleated cells [45], thus avoiding
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confounding with serum creatinine related to its metabolism from muscle. Since creatinine
and cystatin C are correlated measures of kidney function, associations present with both
creatinine and cystatin C-based eGFR suggest a kidney function, rather than an individual
biomarker, effect. Thus, associations between higher ln-urine thallium and higher levels of
both serum creatinine- and cystatin-C-based glomerular filtration measures are consistent
with a kidney function effect such as reverse causality or thallium-related hyperfiltration.
Reverse causality implies that lower urine thallium levels reflect less kidney excretion of
thallium due to chronic kidney disease. In contrast, thallium-related hyperfiltration implies
an effect of the metal on kidney function. Hyperfiltration is a longitudinal process reported
in humans with diabetes, hypertension, and obesity [46] and lead-exposed rodents [47], in
which an initial increase in glomerular filtration rate is followed by a subsequent decline
indicative of chronic kidney disease. We attempted to distinguish between these two
hypotheses in models stratified by median outcome. The fact that thallium associations are
confined to participants with filtration measures below the median is supportive of reverse
causality. However, the two populations stratified by median outcome have a number of
differences in terms of age, sex and lead worker status and, since this is an occupational
population, few participants have kidney dysfunction to the extent necessary to result in
reverse causality.
Antimony and cadmium associations were observed with serum creatinine- but not cystatin-
C-based filtration measures and so neither hypothesis above is as relevant. As previously
published, a statistical mechanism related to the use of creatinine in both exposure and
outcome metrics is a consideration for these associations [9]. The striking change in urine
creatinine associations when a statistically significant metal is in the model, as evidenced by
Models 1 and 2 (Tables 3 and 4) lends support for this mechanism. However, given the
differences in associations between metals, unique metal-specific mechanisms, such as
metal-protein binding affecting excretion [48] must also be considered. Adding to the
complexity of interpreting these findings is a recent publication in which lower levels of
urinary bisphenol A were observed in NHANES participants with lower MDRD eGFR
levels, but not using a different creatinine-based eGFR measure [49].
We were able to exclude several potential hypotheses. Thallium associations cannot be
attributed to lead-related hyperfiltration in this analysis since we adjusted for lead dose;
moreover, urine thallium was positively associated with eGFR even in former workers in
whom lead-related hyperfiltration was not apparent. We were also able to exclude metal
collinearity by observing consistent association directions in simpler a priori models and
evaluating variance inflation factors in fully adjusted models. As an additional check on our
models, BMI, a traditional chronic kidney disease risk factor, was significantly and
negatively associated (i.e., direction consistent with nephrotoxicity) with MDRD eGFR.
Novel results were also observed in the multiple metals analysis. Although common in
environmental exposure, mixtures are infrequently evaluated in research. Co-exposures to
metals with common target organs may have additive or multiplicative effects. A recent
analysis of 1999–2006 NHANES data found that increased blood cadmium and lead levels
were independently associated with increased prevalences of albuminuria and reduced eGFR
[50]. Furthermore, odds of having both outcomes were four-fold higher in participants in the
highest quartiles of both metals compared to those in the lowest. However, in the current
analysis, attenuation was observed. In particular, NAG is routinely used in nephrotoxicant
research. If we had limited our analysis to associations between antimony and thallium in
separate models of NAG, we would have concluded that the results supported nephrotoxicity
from both metals at these levels of exposure. Instead, our multiple metal analysis allowed us
to identify cadmium as the primary toxicant associated with NAG. The antimony attenuation
observed in our analysis may be related to measurement uncertainty, given the large
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proportion of samples below the MDL, or to population differences due to higher exposure
in the lead battery workers.
In conclusion, we report two novel and important findings in these data. First, urine thallium
levels were significantly associated with both serum creatinine- and cystatin-C-based
glomerular filtration measures in the direction opposite to that traditionally reported with
nephrotoxicity. Second, the analysis of multiple metals revealed attenuation of observed
associations by other metals. These results suggest that interpretation of low-level urine
metal values may be more complex than previously thought. Furthermore, single metal
exposure analysis approaches might increase the potential for inaccurate risk conclusions.
Additional research is needed to determine the mechanism(s) for associations between
higher urine metal concentrations and higher glomerular filtration measures.
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What is known
Environmental exposure to multiple metals is common and chronic kidney disease is
increasingly prevalent. However, few epidemiologic studies have examined the impact of
metal co-exposure on kidney function measures such as glomerular filtration rate
estimates.
What this study adds
This study reports additional associations between urine metal levels and glomerular
filtration measures in a direction opposite to that expected in nephrotoxicity. Given
similarities to associations recently observed with cadmium, these results suggest that
interpretation of urine metal values, at exposure levels currently present in the
environment, may be more complex than previously appreciated. This analysis also
revealed attenuation of thallium and antimony associations with NAG, a commonly used
kidney biomarker, following adjustment with cadmium.
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